A Phase 2 Study of Ado-Trastuzumab Emtansine in People With Salivary Gland Cancer


Full Title

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas


Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.

Doctors hope that this treatment lowers the chance of salivary gland cancer coming back. T-DM1 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have operable salivary gland cancer (stage 2 to 4B) that makes the HER2 protein.
  • Not have had prior radiation therapy or chemotherapy for head and neck cancer.
  • Not have received previous HER2-targeted therapy.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Alan Ho’s office at 646-608-3774.




Phase II (phase 2)



ClinicalTrials.gov ID